Drug Approval | November 26, 2021
Aadi Bioscience secures U.S FDA approval of its first product Fyarro
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
It is estimated that one-third of our country’s population has some form of these disorders
The Indian medical devices industry has been in focus since the pandemic. From US $ 11 billion in 2020 it is expected to touch US $ 50 billion by 2025. Mehernosh Daruwalla, Founder and MD, Lotus Surgicals shares a perspective with Thomas C Thottathil on the opportunities in this sector
Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales
Cryo-technology helps in early diagnosis and palliative care in later stages of cancer
Obseva announced previously that the company has entered into a partnership with Syneos Health to support commercialization of linzagolix in the US and EU
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
.jpg)
Molbio Diagnostics has been the pioneer in providing access to molecular testing through its Truenat Real Time PCR platform. Sriram Natarajan, Director & CEO, of the company shares his experiences on the journey so far in an interview with Thomas C Thottathil
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC
Subscribe To Our Newsletter & Stay Updated
